Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program

Published:2023-01-10 Issue:3 Volume:64 Page:619-629
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Szaflarski Jerzy P.¹^ORCID,Devinsky Orrin²^ORCID,Lopez Merrick³,Park Yong D.⁴,Zentil Pilar Pichon⁵,Patel Anup D.⁶^ORCID,Thiele Elizabeth A.⁷^ORCID,Wechsler Robert T.⁸,Checketts Daniel⁹,Sahebkar Farhad¹⁰^ORCID

Affiliation:

1. Department of Neurology, UAB Epilepsy Center, Heersink School of Medicine University of Alabama at Birmingham Birmingham Alabama USA

2. Comprehensive Epilepsy Center NYU Langone Health New York New York USA

3. Pediatric Critical Care Medicine Loma Linda University Children's Hospital Loma Linda California USA

4. Pediatric Neurology Medical College of Georgia, Augusta University Augusta Georgia USA

5. Pediatric Neurology Loma Linda University Children's Hospital Loma Linda California USA

6. Neurology and Pediatrics Nationwide Children's Hospital Columbus Ohio USA

7. Pediatric Neurology Massachusetts General Hospital Boston Massachusetts USA

8. Consultants in Epilepsy & Neurology and Idaho Comprehensive Epilepsy Center Boise Idaho USA

9. Biostatistics Jazz Pharmaceuticals, Inc. Carlsbad California USA

10. Clinical Development Jazz Pharmaceuticals, Inc. Carlsbad California USA

Funder

New York State Department of Health

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.17496

Reference29 articles.

1. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

2. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial

3. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

4. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

5. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subthreshold Cannabidiol Potentiates Levetiracetam in the Kainic Acid Model of Temporal Lobe Epilepsy: A Pilot Study;Pharmaceuticals;2024-09-10

2. Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program;Epilepsia Open;2024-08

3. Endocannabinoid System and Neuromodulation in Neurodegenerative Diseases: A Focus on Neuropsychiatric Symptoms;J BIOL REG HOMEOS AG;2024

4. Correction to “Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program”;Epilepsia;2024-03-19

5. Cannabidiol: metabolism and clinical efficacy in epileptic patients;Expert Opinion on Drug Metabolism & Toxicology;2024-03-03